

# [TTF1, napsin A tests for lung cancer diagnostics](#)

written by CAP TODAY  
February 20, 2021

February 2021—Novodiya launched two rapid IHCDirect antibody assays, TTF1 and napsin A, for in vitro diagnostic use.



©2026 CAP TODAY, all rights reserved.

---

# [Markers, methods remake the NSCLC map](#)

written by CAP TODAY  
February 20, 2021

February 2021—Absorbing new biomarkers into lung cancer workups makes for a complicated diplomacy. How best to balance so many rivals? Does it make the most sense for laboratories to try to do everything at once, a full-court press involving next-generation sequencing panels? Or is it more practical to add a new marker only as a new targeted therapy receives approval? Where do RNA-based assays fit in? What about IHC? When do you make the switch? Or do you? And how best to handle cell-free DNA tests (which seem to be the rogue states in all this)? How do you weight external factors, such as reimbursement, existing equipment and capital expenditures, and physician expertise? Driving this all are medical breakthroughs. As with all forms of statecraft, the latest incident can change everything. For lung cancer, the most recent advance comes from the ADAURA trial, which showed a significant benefit of using osimertinib to treat stage IB to IIIA *EGFR*-mutation positive non-small-cell lung cancer.



©2026 CAP TODAY, all rights reserved.

---

## **BD gets EUA, CE mark for combo SARS-CoV-2, flu A+B test**

written by CAP TODAY  
February 20, 2021

Feb. 19, 2021—BD announced FDA emergency use authorization for a molecular diagnostic test for SARS-CoV-2 and influenza A and B that can return results in two to three hours. The test also has been CE marked to the IVD directive.



©2026 CAP TODAY, all rights reserved.

---

## **Setting sights on a coordinated testing strategy**

written by CAP TODAY  
February 20, 2021

February 2021—From the first, the COVID-19 pandemic has been marked by absence. Reagents and instruments, collection tubes and pipette tips; enough technologists to handle the overwhelming workloads; sleep—so much went missing or was in short supply, month after month.



©2026 CAP TODAY, all rights reserved.

---

# [In transplantation, detecting CMV antiviral resistance](#)

written by CAP TODAY  
February 20, 2021

February 2021—Eighteen months after introducing a next-generation sequencing assay to detect CMV antiviral resistance in the transplant population, Matthew Binnicker, PhD, D(ABMM), in an AMP presentation, shared a patient’s case and his laboratory’s broader experience.



©2026 CAP TODAY, all rights reserved.

---

# [New data on reference ranges for transgender men](#)

written by CAP TODAY  
February 20, 2021

February 2021—Cisgender male reference intervals can be used to interpret testosterone concentrations in transgender and nonbinary adults on masculinizing therapy, but reference intervals specific to the transmasculine population should be used to evaluate estradiol, say the authors of a recently published study.



©2026 CAP TODAY, all rights reserved.

---

# [Variants, vaccines, predictions: Compass on COVID](#)

written by CAP TODAY  
February 20, 2021

February 2021—Variants and vaccines were in the news when Compass Group members spoke with CAP TODAY publisher Bob McGonnagle for the first time in the new year, on Jan. 5. “This is something we all need to stay close to,” Julie Hess, of AdventHealth, said of the variants. “We need to know if it’s going to impact our ability to detect.” With McGonnagle and Hess on the Jan. 5 call were Dwayne Breining, MD, and James Crawford, MD, PhD, Northwell; John Waugh, MS, MT(ASCP), Henry Ford; Stan Schofield, MaineHealth; Gregory Sossaman, MD, Ochsner; Peter Dysert, MD, Baylor Scott & White; Steven Carroll, MD, PhD, Medical University of South Carolina; Heather Dawson, Allina; Janet Durham, MD, ACL; Daniel Ingemansen, Sanford Health; Ericka Olgaard, DO, MBA, University of Arkansas for Medical Sciences; Sterling Bennett, MD, MS, Intermountain; and Judy Lyzak, MD, MBA, Alverno.



©2026 CAP TODAY, all rights reserved.

---

## [Finding the morphologic clues to neutrophilia etiology](#)

written by CAP TODAY  
February 20, 2021

February 2021—Granulocyte morphology may contain clues to neutrophilia etiology, and that was the focus of a CAP20 virtual presentation by Olga Pozdnyakova, MD, PhD, associate professor of pathology at Harvard Medical School and medical director of the hematology laboratory at Brigham and Women’s Hospital. Reactive changes can mimic myeloproliferative neoplasm, but myeloproliferative neoplasm can have reactive morphology, she said. Pathologists can piece together clinical and morphological clues, “especially in concert with the clinical team, that may help them decide whether the changes are more reactive or more neoplastic in nature,” she told CAP TODAY in a follow-up interview. Neutrophilia is defined as greater than  $7.7 \times 10^9/L$  or two standard deviations above the mean, and it is important to note whether it is present in the context of the left shift.

## **CAP TODAY Roundtable: AP computer system— ‘Look at value versus cost’**

written by CAP TODAY  
February 20, 2021

February 2021—What is the one most important thing to look for in an anatomic pathology computer system? That is one of several questions CAP TODAY publisher Bob McGonnagle put to five people in a Dec. 14 call on the AP LIS and more—surgical pathology volumes amid COVID-19, data integration, practice consolidation.

## **Surgical Pathology Review: easing the transitions**

written by CAP TODAY  
February 20, 2021

*February 2021—New from CAP Publications is Surgical Pathology Review, by Daniel D. Mais, MD, associate professor of pathology, Department of Pathology, University of Texas Long School of Medicine, San Antonio. He and 14 other contributors wrote this book to ease the transition through board exams and into practice, Dr. Mais writes in the preface. Here is what he told CAP TODAY about the book.*



©2026 CAP TODAY, all rights reserved.